#High mpv autoimmune trial
We are encouraged by the safety profile demonstrated by our DSG3-CAART in the DesCAARTes™ Phase 1 trial to date, and based on emerging translational data, we are employing combination strategies to increase DSG3-CAART cell activity. Over the past five years, our robust track record of execution has yielded two clinical-stage programs that are elegantly designed to target only the cells responsible for disease. Since Cabaletta Bio was founded in 2017, we have been working toward a singular goal: Developing and launching the first curative targeted cellular therapies for patients with autoimmune diseases. To harness the immune system through innovative cell and gene therapies to deliver accessible cures for patients. The MusCAARTes™ trial for our MuSK-CAART candidate in MuSK-associated myasthenia gravis is progressing into a Phase 1 clinical trial, and we have advanced several other high-priority targets into discovery and preclinical testing. Our most advanced CAART candidate, DSG3-CAART, is being evaluated in the DesCAARTes™ trial, which is a Phase 1 study for the treatment of patients with mucosal-dominant pemphigus vulgaris (mPV). Our lead CARTA candidate, CABA-201, is being developed in autoimmune diseases with high unmet need.Ĭabaletta’s proprietary Chimeric AutoAntibody Receptor T (CAART) cell approach is designed for diseases driven by specific autoantibodies, to enable permanent elimination of only disease-causing B cells with preservation of the healthy immune system. The Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) approach is designed to enable transient eradication of all B cells in patients with autoimmune diseases driven by B cells, with subsequent repopulation of normal B cells, thus resetting the immune system and restoring immune health. The CABA™ platform has potential applicability across many B cell-mediated autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, myositis, systemic sclerosis, pemphigus vulgaris and myasthenia gravis, and it encompasses two approaches. Our proprietary Cabaletta Approach to B cell Ablation (CABA™) platform is designed to provide deep, durable, and potentially curative responses with one-time administration, with the possibility of eliminating the need for chronic immune suppressive therapies. On a proven foundation of CAR T technology and an established track record of clinical operational excellence in cell therapy in autoimmunity, we are developing innovative engineered T cell therapies for patients with autoimmune diseases. What if autoimmune diseases could be cured with a one-time treatment? At Cabaletta Bio, we believe it is possible.
0 kommentar(er)
